Sexual dimorphic response to rituximab treatment: A longitudinal observational study in a large cohort of patients with primary membranous nephropathy and persistent nephrotic syndrome
Rituximab is one of the first-line therapies for patients with membranous nephropathy (MN) at high risk of progression towards kidney failure. We investigated whether the response to Rituximab was affected by sex and anti-PLA2R antibody levels in 204 consecutive patients (148 males and 56 females) w...
Saved in:
Main Authors: | Annalisa Perna (Author), Barbara Ruggiero (Author), Manuel Alfredo Podestà (Author), Luca Perico (Author), Silvia Orisio (Author), Hanna Debiec (Author), Giuseppe Remuzzi (Author), Piero Ruggenenti (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2022-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Spironolactone Plus Full-Dose ACE Inhibition in Patients with Idiopathic Membranous Nephropathy and Nephrotic Syndrome: Does It Really Work?
by: Giuseppe Remuzzi, et al.
Published: (2010) -
Rituximab in patients with membranous nephropathy and kidney insufficiency
by: Yanhong Guo, et al.
Published: (2022) -
Efficacy and safety of rituximab in elderly patients with membranous nephropathy
by: Yanhong Guo, et al.
Published: (2023) -
Two cases of idiopathic membranous nephropathy treated with rituximab
by: Jae Young Yoon, et al.
Published: (2013) -
Therapeutic advances of rituximab alone or plus other drugs for membranous nephropathy
by: Chao Zhang, et al.
Published: (2024)